中 | EN

Investors

VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SERUM-FREE RABIES VACCINE ACHIEVED SATISFACTORY PHASE RESULTS
2023-09-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
2023-09-05
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
2023-09-05
VOLUNTARY ANNOUNCEMENT - THE APPROVAL FOR THE ISSUANCE OF UNLISTED RMB DENOMINATED ORDINARY SHARES FROM THE CSRC
2023-08-30
VOLUNTARY ANNOUNCEMENT - INITIATION OF RANDOMIZED, BLINDED AND COMPARABLE VACCINE-CONTROLLED PHASE III CLINICAL TRIAL OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE
2023-08-29
2023 INTERIM REPORT
2023-08-29
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
2023-08-29
NOTICE OF BOARD MEETING
2023-08-17
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
2023-08-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
2023-07-03
VOLUNTARY ANNOUNCEMENT - BIVALENT mRNA VACCINE AGAINST COVID-19 VARIANTS DELTA AND OMICRON BA.5 OBTAINED CLINICAL TRIAL APPROVALS FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION
2023-06-29
VOLUNTARY ANNOUNCEMENT - APPLICATION ACCEPTED FOR CLINICAL TRIAL OF HUMAN RABIES mRNA VACCINE AGAINST RABIES VIRUS
2023-06-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
2023-06-01
VOLUNTARY ANNOUNCEMENT MAJOR RESULTS OF A DOMESTIC STUDY ON PROTECTIVE EFFICACY OF COVID-19 VARIANT OMICRON BA.5 mRNA VACCINE LVRNA012
2023-06-01
POLL RESULTS OF THE ANNUAL GENERAL MEETING, THE 2023 SECOND CLASS MEETING FOR HOLDERS OF DOMESTIC SHARES AND THE 2023 SECOND H SHARE CLASS MEETING HELD ON MAY 28, 2023
2023-05-28
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
2023-05-04
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING, THE CLASS MEETING FOR HOLDERS OF DOMESTIC SHARES AND THE H SHARE CLASS MEETING HELD ON APRIL 28, 2023
2023-04-28
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE 2023 SECOND H SHARE CLASS MEETING TO BE HELD ON MAY 28, 2023
2023-04-21
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 28, 2023
2023-04-21
NOTICE OF THE 2023 SECOND H SHARE CLASS MEETING
2023-04-21
NOTICE OF 2022 ANNUAL GENERAL MEETING
2023-04-21
2022 CIRCULAR OF ANNUAL GENERAL MEETING
2023-04-21
FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE 2023 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON APRIL 28, 2023
2023-04-11
FORM OF PROXY FOR THE 2023 FIRST H SHARE CLASS MEETING TO BE HELD ON APRIL 28, 2023
2023-04-11
NOTICE OF H SHARE CLASS MEETING
2023-04-11
NOTICE OF EXTRAORDINARY GENERAL MEETING
2023-04-11
PROPOSED ISSUANCE OF UNLISTED RMB DENOMINATED ORDINARY SHARES UNDER SPECIFIC MANDATE, NOTICE OF THE EXTRAORDINARY GENERAL MEETING AND NOTICE OF THE H SHARE CLASS MEETING
2023-04-11
CLOSURE OF REGISTER OF MEMBERS
2023-04-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
2023-04-03
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
2023-03-29
NOTICE OF BOARD MEETING
2023-03-17
VOLUNTARY ANNOUNCEMENT - TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE CANDIDATE OFFICIALLY COMMENCED CLINICAL TRIAL
2023-03-17
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS; BUSINESS UPDATES
2023-03-14
INSIDE INFORMATION-(1) PROPOSED ISSUANCE OF UNLISTED RMB DENOMINATED ORDINARY SHARES (2) PROPOSED AUTHORIZATIONS TO THE BOARD RELATING TO THE PROPOSED ISSUANCE (3) PROPOSED EGM AND CLASS MEETINGS
2023-03-08
PROFIT WARNING
2023-03-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
2023-03-01
VOLUNTARY ANNOUNCEMENT - MRNA COVID-19 VACCINE CANDIDATES AGAINST COVID-19 VARIANTS AND ORIGINAL STRAIN OBTAINED CLINICAL TRIAL APPROVALS IN PAKISTAN
2023-02-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
2023-02-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
2023-01-06
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
2023-01-06
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
2023-01-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
2022-12-01
Next Day Disclosure Return
2022-11-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
2022-11-01
VOLUNTARY ANNOUNCEMENT —— EV71-CA16 BIVALENT HFMD VACCINE CANDIDATE OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
2022-10-31
PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
2022-10-28
VOLUNTARY ANNOUNCEMENT —— FREEZE-DRIED HUMAN RABIES VACCINE CANDIDATE (SERUM-FREE VERO CELL) OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
2022-10-24
Announcement of Allotment Results
2022-10-05
Articles of Association
2022-10-05
Terms of Reference of the Audit Committee of the Board of Directors
2022-10-05
Terms of Reference of the Remuneration and Appraisal Committee of the Board of Directors
2022-10-05
Terms of Reference of the Nomination Committee of the Board of Directors
2022-10-05
List of Directors and Their Roles and Functions
2022-10-05
GLOBAL OFFERING 
2022-09-23
GLOBAL OFFERING
2022-09-23
GREEN APPLICATION FORM
2022-09-23
© 2022 艾美疫苗股份有限公司 All rights reserved. 京ICP备20027818号-1 京公网安备11010502045274号